CoChat

Open Study of the Catechol-O-Methyltransferase Inhibitor Tolcapone in Major Depressive Disorder

Fava, Maurizio, Rosenbaum, Jerrold F., Kolsky, Andrea R., Alpert, Jonathan E., Nierenberg, Andrew A., Spillmann, Maya, Moore, Constance, Renshaw, Perry, Bottiglieri, Teodoro, Moroz, Georges, Magni, Guido · 1999 · Journal of Clinical Psychopharmacology
Cited by 59

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Tolcapone is a catechol-O-methyltransferase (COMT) inhibitor that has shown efficacy in the treatment of Parkinson's disease. The authors undertook the first study on the efficacy of this COMT inhibitor in the treatment of major depressive disorder (MDD). The authors also wanted to assess the effects of tolcapone on the choline and myoinositol resonances in the left caudate and dorsolateral frontal lobe through proton magnetic resonance spectroscopy and on whole blood levels of S-adenosyl-L-methionine (SAMe). The study enrolled 21 adults (10 men and 11 women; mean age, 42.6 +/- 9.6 years) with MDD, which was diagnosed using the Structured Clinical Interview for DSM-IV, and an initial score of > or = 16 on the 17-item Hamilton Rating Scale for Depression (HAM-D-17). Patients were then treated openly for 8 weeks with tolcapone 400 mg twice daily. Treatment efficacy was assessed with the HAM-D-17, the Clinical Global Impressions Severity (CGI-S) scale, and the Beck Depression Inventory (BDI). Among all subjects (N = 21), there were significant (p < .0001) decreases at endpoint in HAM-D-17 scores (from 19.4 +/- 2.9 to 10.7 +/- 5.5), CGI-S scores (from 3.9 +/- 0.6 to 2.4 +/- 1.1), and BDI scores (from 21.6 +/- 8.1 to 12.3 +/- 8.6). Eight patients (38%) dropped out before completing the 8-week open study because of diarrhea, elevated liver function tests, increased anxiety, and noncompliance. No significant effects were noted on choline and myoinositol resonance or on SAMe levels in whole blood before and after 2 weeks of tolcapone treatment. The preliminary results suggest that tolcapone may be a promising agent in the treatment of MDD. Furthermore, double-blind, placebo-controlled studies are necessary to confirm this impression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00004714-199908000-00008

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 59

Metadata

Authors
Fava, M., Rosenbaum, J. F., Kolsky, A. R., Alpert, J. E., Nierenberg, A. A., Spillmann, M., Moore, C., Renshaw, P., Bottiglieri, T., Moroz, G., & Magni, G.
Venue
Journal of Clinical Psychopharmacology
Published
1999-08
Volume
19
Issue
4
Pages
329-335
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2055958700
Cited by
59
References
1
FWCI
1.01
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Open Study of the Catechol-O-Methyltransferase Inhibitor Tolcapone in Major Depressive Disorder. https://app.cochat.ai/papers/10.1097/00004714-199908000-00008
The paper
Fava, M., Rosenbaum, J. F., Kolsky, A. R., Alpert, J. E., Nierenberg, A. A., Spillmann, M., Moore, C., Renshaw, P., Bottiglieri, T., Moroz, G., & Magni, G. (1999). Open Study of the Catechol-O-Methyltransferase Inhibitor Tolcapone in Major Depressive Disorder. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199908000-00008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.